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In a recent issue of the Journal of Thrombosis and Hae-
mostasis, we published a study demonstrating that phos-
phorothioate (PS)-modified CpG oligodeoxynucleotides
(PS-CpG ODNs) types A, B and C activate platelets via
CLEC-2 [1]. This study followed an initial article by Flierl
et al. showing that PS-CpG ODN type C exerts a platelet
activating effect through GPVI [2]. In a Letter to the Edi-
tor, Flierl et al. now present new computational modeling
data confirming that PS-CpG ODN type C can bind to
CLEC-2 monomers or homodimers, or even to two
homodimers, and would therefore be able to cause recep-
tor clustering on the platelet surface. Then, by using ran-
dom PS-ODNs of different size, the authors determined
the minimum number of nucleotides required for binding
to platelets, aIIbb3 integrin activation or P-selectin expo-
sure. They found that six PS-modified nucleotides are
needed to obtain significant ODN binding to platelets,
whereas the induction of significant integrin activation
and P-selectin requested at least 10-mer and 18-mer,
respectively.
These data do not fit with our observation that type A
CpG ODNs, with only eight PS-modified nucleotides,
potently activate human washed platelets, and induce
their immediate aggregation, whereas type C CpG ODN,
with a full 22-mer PS backbone, only weakly bind to
human washed platelets, hardly activate them, and do not
induce aggregation in washed platelet suspensions [1].
This is even more surprising because we showed that
human washed platelets aggregate in response to type B
CpG ODN that contain 24 PS nucleotides.
We believe that not only size, but also sequences, mat-
ter when considering CpG ODN-induced platelet activa-
tion.
First, as a result of binding of poly(G) motifs to scav-
enger receptors on the cell surface, CpG ODN type A
that contain these motifs are expected to display an
increase in cellular uptake efficiency [3]. This is consistent
with our data obtained with human washed platelets,
showing more efficient uptake of type A CpG ODN than
type B (FITC-CpG ODN binding to platelets after
30 min incubation: type A = 25219  2317; type
B = 2143  743; values = means MFI  SD).
Second, it has been reported that the differential effects
of types A, B and C CpG ODN on immune cells very
much rely on higher-order tertiary structures that form in
a sequence-dependent manner. For instance, the greater
ability of type A CpG ODN to induce IFN-a production
by plasmacytoid dendritic cells (pDC) than type B CpG
ODN has been related to the higher-order structure of
the A type [4,5]. Indeed, because of the presence of a
palindromic sequence at the center of the ODN and poly
(G) at its 50 and 30 end, type A CpG ODN spontaneously
self-assembles to higher-order tertiary structures (G-tet-
rads), forming nanometer-size particles [5]. Such higher-
order structures are not observed in type B CpG ODNs
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Fig. 1. Fibronectin, and to a lesser extent fibrinogen, contribute to CpG ODN type C-induced platelet activation. (A) Flow cytometric analysis
of FITC-conjugated CpG ODN C uptake by human washed platelets without (C) or in the presence of normal plasma, Fn- or Fg-depleted
plasma, or of a mixture of purified Fn and Fg (250 lg mL1) (***P < 0.001 vs. C, n = 4–8). (B) Amplitude of aggregation induced by CpG
ODN type C (10 lM) in human washed platelet suspensions supplemented with normal plasma, fibronectin (Fn)- or fibrinogen (Fg)-depleted
plasma (**P < 0.01 vs. normal plasma, n = 5). (C) Flow cytometric analysis of CpG ODN C (10 lM) induced P-selectin exposure (left panel)
or of FITC-conjugated CpG ODN C uptake (right panel) performed on washed platelets isolated from control mice (WT) or from b3/ mice
(n = 3) (***P < 0.001 vs. 20 s or NS). NS = non-stimulated.
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harboring a linear structure. Type C CpG ODNs form a
duplex, because of the palindromic sequence at the 30
end, which may explain their ability to induce IFN-a
secretion [6]. The duplex formation of type C CpG ODN
has not been taken into account in the model of Flierl. It
would thus be interesting to model the binding of type C
CpG ODN duplexes or of type A G-tetrads to GPVI and
CLEC-2 and determine the impact of ODN duplexing
or multiplexing on clustering of these platelet surface
receptors.
Third, interactions of CpG ODN with proteins could
also influence their platelet activating effect. Indeed, it has
been shown that type A CpG ODN achieve much of the
INF-a effect through interaction with CXCL16 expressed
on pDC, which enhances the uptake of type A, but not of
type B, CpG ODNs [7]. The possibility that cofactors may
take part in the recognition of one or more CpG ODN
types by platelets has not been investigated yet.
Our own recent work indicates that fibrinogen (Fg) and
fibronectin (Fn) might contribute to CpG ODN type C-
induced platelet activation. We indeed observed that addi-
tion of plasma to washed platelets significantly increased
CpGODNC uptake (Fig. 1A), which could not be achieved
by using plasma depleted in Fn or in Fg. Moreover, the
addition of purified Fn and Fg to washed platelet suspen-
sions increased CpG ODN C uptake similarly to normal
plasma. Upon supplementation with normal plasma, CpG
ODN type C efficiently induced the aggregation of washed
platelets, whereas this platelet response was much weaker in
the presence of Fn-depleted plasma (Fig. 1B). Altogether,
these results suggest that CpG ODN type C might interact
with Fg and Fn, two major plasma proteins, which may pro-
mote ODN uptake and subsequent platelet activation. On
the platelet surface, the aIIbb3 integrin represents the main
common receptor for Fg and Fn, whereas fibronectin can
also bind to a5b1, GPIb/V/IX andGPVI.We thus wanted to
assess the role of aIIbb3 integrin in CpG ODN C-induced
platelet activation.We found that the aIIbb3 integrin antago-
nist, tirofiban, significantly reduced CpG ODN C uptake
and CpG ODN C-induced P-selectin exposure on the plate-
let surface by 44  17% and 50  14%, respectively
(P < 0.01). Furthermore, CpG ODN uptake and P-selectin
exposure were abrogated in b3-deficient mouse platelets
(Fig. 1C).
Because plasma Fn can bind PS-modified DNA [8] and
can be taken up by platelets via aIIbb3 integrin [9], this
mechanism could also contribute to CpG ODN uptake,
in addition to CLEC-2. Furthermore, because plasma Fn
deposits rapidly onto the injured vessel wall, prior to pla-
telets [10], the interaction of CpG ODN with deposited
fibronectin might enhance its interaction with platelets,
and promote subsequent thrombus formation.
In conclusion, the new set of data support the involve-
ment of multiple platelet receptors in CpG ODN platelet
activating effects. We observed some sequence-specific
features of platelet responses to PS-modified CpG ODNs
types A, B and C that could be useful for future develop-
ment of safe therapeutic CpG ODNs. However, further
investigations are needed in order to further delineate
these sequence specificities, and to address the importance
of higher-order structures, as well as of possible interac-




All oligodeoxynucleotides with phosphorothioate modifi-
cation were from Invivogen (Toulouse, France). Type A
(2216), B (2006) and C (2395) CpG ODN were used.
Human fibrinogen was from Haematologic Technologies
Inc. (Essex Junction, VT, USA) and human fibronectin
from CoaChrom Diagnostica (Maria Enzersdorf, Aus-
tria). Fibrinogen- and fibronectin-deficient human plasma
were from Stago (Asnieres-sur-Seine, France) and Innova-
tive Research (Novi, MI, USA), respectively.
Mice
b3 knockout mice and their littermates were provided by
Jochen Schneider. All mice were kept under specific
pathogen-free conditions. Eight to 12-week-old male mice
were used in all experiments. All animal care and experi-
mental procedures were performed as recommended by
the European Community Guidelines (directive 2010/63/
UE) and approved by the Ethical Committee of the
University of Liege.
Preparation of human and mouse washed platelets
Human and mouse washed platelets were prepared from
freshly drawnACD-anticoagulated blood according to stan-
dard procedures [1]. All procedures on human blood were
approved by our institutional review committee (Comite
d’Ethique Hospitalo-Facultaire Universitaire de Liege). The
healthy volunteers gave written informed consent.
Platelet aggregation analyses
Light transmission was recorded during platelet aggrega-
tion induced by CpG ODNs on a Chrono-Log Lumi-
Aggregometer (Kordia, Leiden, the Netherlands).
Flow cytometry
Platelet degranulation was assessed with flow cytometry
by measuring the expression of P-selectin (PE-conjugated
anti-mouse CD62P, BD Biosciences, Erembodegem, Bel-
gium). In binding experiments, FITC-conjugated ODNs
were incubated with platelets for increasing amounts of
time. Samples were analyzed on a FACSVerse flow
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cytometer using the FACSuite software (BD Biosciences,
Erembodegem, Belgium).
Statistics
Data are presented as mean  SD of at least three indepen-
dent experiments. Three or more groups were compared
using one-way ANOVA and the Bonferroni multiple compar-
ison test. A P-value < 0.05 was considered statistically sig-
nificant. Calculations were performed using GraphPad-
Prism (GraphPad Software, Inc., La Jolla, CA, USA).
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